The following is a listing of myeloma treatments associated with this tag.
View all treatments in development for myeloma patients around the US.
Mezagitamab
Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.
Nivolumab
Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
SEA-BCMA
SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.
Mezagitamab
Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.
Nivolumab
Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.
Mezagitamab
Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.
Nivolumab
Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
SEA-BCMA
SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with Smoldering Myeloma.
Nivolumab
Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
The following is a listing of myeloma clinical trials associated with this tag.
View all active clinical trials around the US.
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
DARATUMUMAB COMBINATION THERAPY
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
DARATUMUMAB FOR PATIENTS WITH KIDNEY FAILURESparkCures Verified Accurate, up-to-date information. Learn more
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
CD38-TARGETED IMMUNOPETA Multi-Center, Phase 1 Trial of Combining Anti-CD47 Antibody (Magrolimab) With Azacitidine as Post-Transpl...
MAGROLIMAB AND AZACITIDINE MAINTENANCEA Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Relate...
MISMATCHED RELATED VS. MATCHED UNRELATED DONORA Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
IPILIMUMAB PLUS DONOR LYMPHOCYTE INFUSIONA Phase 1a/b Study to Evaluate the Safety & Tolerability of JSP191 in Combination With a Regimen of Low Dos...
JSP191 CONDITIONING REGIMENA Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a ...
TRIPLET INDUCTION + 1 OR 2-DRUG MAINTENANCEA Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination W...
AK117/PLACEBO WITH AZACITIDINECardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS)...
HEART PROTECTION W/DEXRAZOXANE DURING CHEMOTHERAPYIsatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
ISATUXIMAB DURING STEM CELL TRANSPLANTIsatuximab Plus Lenalidomide and Dexamethasone for Frail and/or Much Older Patients With Newly Diagnosed Mu...
ISATUXIMAB IN FRAIL PATIENTSIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multip...
ISATUXIMAB COMBINATION THERAPYPembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cel...
PEMBROLIZUMAB AS SALVAGE THERAPYPhase 1b Study of Pembrolizumab, Decitabine +/- Venetoclax Combination Therapy in Patients With Relapsed or...
PEMBROLIZUMAB, DECITABINE +/- VENETOCLAXPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDEPilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD...
DARATUMUMAB FOR PATIENTS WITH RENAL FAILUREPost-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
POST-TRANSPLANT MAINTENANCE THERAPYSafety and Efficacy of Elotuzumab, CC-92480, and Dexamethasone in Relapsed/Refractory Myeloma After CD38- a...
ELOTUZUMAB COMBINATION THERAPYSteroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
DARATUMUMAB AND LENALIDOMIDE FOR NDMMT Cell Receptor Alpha/Beta T Cell Depleted (α/β TCD) Hematopoietic Cell Transplantation in Patients With Fa...
T CELL RECEPTOR DEPLETION IN STEM CELL TRANSPLANT²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor...
²¹¹AT-OKT10-B10 WITH FLUDARABINEThe following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
DARATUMUMAB FOR PATIENTS WITH KIDNEY FAILURESparkCures Verified Accurate, up-to-date information. Learn more
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
CD38-TARGETED IMMUNOPETA Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a ...
TRIPLET INDUCTION + 1 OR 2-DRUG MAINTENANCEIsatuximab Plus Lenalidomide and Dexamethasone for Frail and/or Much Older Patients With Newly Diagnosed Mu...
ISATUXIMAB IN FRAIL PATIENTSPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDESteroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
DARATUMUMAB AND LENALIDOMIDE FOR NDMM²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor...
²¹¹AT-OKT10-B10 WITH FLUDARABINEThe following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
DARATUMUMAB COMBINATION THERAPYSparkCures Verified Accurate, up-to-date information. Learn more
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
CD38-TARGETED IMMUNOPETIsatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
ISATUXIMAB DURING STEM CELL TRANSPLANTIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multip...
ISATUXIMAB COMBINATION THERAPYPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDESafety and Efficacy of Elotuzumab, CC-92480, and Dexamethasone in Relapsed/Refractory Myeloma After CD38- a...
ELOTUZUMAB COMBINATION THERAPY²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor...
²¹¹AT-OKT10-B10 WITH FLUDARABINEThe following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
DARATUMUMAB COMBINATION THERAPYSparkCures Verified Accurate, up-to-date information. Learn more
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
CD38-TARGETED IMMUNOPETIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multip...
ISATUXIMAB COMBINATION THERAPYPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDESafety and Efficacy of Elotuzumab, CC-92480, and Dexamethasone in Relapsed/Refractory Myeloma After CD38- a...
ELOTUZUMAB COMBINATION THERAPY²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor...
²¹¹AT-OKT10-B10 WITH FLUDARABINEThe following is a listing of clinical trials for patients with Smoldering Myeloma.
The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
The following is a listing of myeloma tags that are associated with this tag.
B-Cell Maturation Antigen (BCMA)
B-Cell Maturation Antigen (BCMA) is a protein that may be found on the surface of myeloma cells. BCMA may be used as a target to help treatments find and destroy myeloma cells.
CD38
CD38 is a protein that may be found on the surface of many immune system cells (including multiple myeloma cells). This protein may be used as a way for treatments to target (or find) myeloma cells.
Programmed Death Receptor-1 (PD-1)
PD-1 is a protein found on the surface of immune cells (called T cells). This protein acts as an "off switch" that may stop your immune system from attacking cancer cells.